Pacific Biosciences of California Stock News

Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.

At one point Cathie Wood was the hottest money manager on Wall Street. Her family of Ark Invest exchange-traded funds (ETF) grew at a blistering pace, at one point doubling the returns for investors.

PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key me

Pacific Biosciences of California, Inc. (PACB) Q4 2023 Earnings Call Transcript

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.35 per share a year ago.

You can't say Cathie Wood is afraid to make big bets. The investing guru is more than willing to lay it all on the line for stocks she believes in.

PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.

PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.

PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.

MENLO PARK, Calif. , Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting